References
- Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021 Sep 7;73(5):755–757. doi: 10.1093/cid/ciab718
- Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021 Jun 1;116(6):1124–1147. doi: 10.14309/ajg.0000000000001278
- van Prehn J, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1–S21.
- Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022 Jan 20;386(3):220–229. doi: 10.1056/NEJMoa2106516
- McGovern BH, Ford CB, Henn MR, et al. SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: lessons learned from a phase 2 trial. Clin Infect Dis. 2021 Jun 15;72(12):2132–2140. doi: 10.1093/cid/ciaa387
- Sims MD, Khanna S, Feuerstadt P, et al. Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single-arm trial. JAMA Netw Open. 2023 Feb 1;6(2):e2255758. doi: 10.1001/jamanetworkopen.2022.55758
- VOWST (fecal microbiota spores, live-brpk) capsules, for oral administration. Prescribing information. [updated Apr 2023; cited May 3, 2023]. Available from: https://www.serestherapeutics.com/our-products/VOWST_PI.pdf
- Food and Drug Administration. Fecal microbiota for transplantation: safety alert - Risk of serious adverse events likely due to transmission of pathogenic organisms. [updated Apr 7, 2020; cited May 3, 2023]. Available from: https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission
- U.S. Department of Health and Human Services, Food and Drug Administration. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridioides difficile infection not responsive to standard therapies: Guidance for industry. [updated Nov 2022; cited May 3, 2023]. Available from: https://www.fda.gov/media/86440/download
- Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016 Jan 12;315(2):142–149. doi: 10.1001/jama.2015.18098
- REBYOTATM (fecal microbiota, live - jslm) suspension, for rectal use [prescribing information]. [updated Nov 2022; cited May 4, 2023]. Available from: https://ferringus2.corporate-us.ferring.tech/wp-content/uploads/sites/12/2022/12/9009000002_REBYOTA-PI_11-2022.pdf
- Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022 Oct;82(15):1527–1538.
- Garey KW, Jo J, Gonzales-Luna AJ, et al. Assessment of quality of life among patients with recurrent Clostridioides difficile infection treated with investigational oral microbiome therapeutic SER-109: secondary analysis of a randomized clinical trial. JAMA Netw Open. 2023 Jan 3;6(1):e2253570. doi: 10.1001/jamanetworkopen.2022.53570
- Hengel RL, Schroeder CP, Jo J, et al. Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life. J Patient Rep Outcomes. 2022 May 14;6(1):49. doi: 10.1186/s41687-022-00456-9
- Sandhu A, Chopra T. Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls. Therap Adv Gastroenterol. 2021;14:17562848211053105.